Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial of lapatinib or Herceptin alongside capecitabine for HER2 positive breast cancer that has spread to the brain (LANTERN)
This trial compared a combination of lapatinib and capecitabine with a combination of Herceptin (also known as trastuzumab) and capecitabine after radiotherapy to the brain for HER2 positive breast cancer that has spread to the brain.
Some breast cancers produce a large amount of a protein called HER2. The HER2 protein makes cancer cells divide and grow. Drugs such as Herceptin block HER2 and can stop cancer cells growing.
People who took part in this trial had breast cancer that had spread to their brain. They had already had chemotherapy and Herceptin as well as radiotherapy to the brain.
Everybody had the chemotherapy drug capecitabine. Some people had Herceptin with the chemotherapy. Some had another drug called lapatinib with the chemotherapy. Lapatinib also blocks the HER2 protein.
The aim of the study was to find out which of the 2 drugs works best when given alongside capecitabine for HER2 positive breast cancer that has spread to the brain.
Summary of results
This trial was never finished so there are no results available. The researchers were unable to recruit enough patients.
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof David Dodwell
Cancer Research UK
Clinical Trials Research Unit (CTRU)
University of Leeds
Experimental Cancer Medicine Centre (ECMC)
Leeds Teaching Hospitals NHS Trust
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUKE/10/046.